Screener
Tango Therapeutics TNGX Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Property and equipment, net | 6,381 | 6,868 |
| Operating lease right-of-use assets | 34,652 | 35,624 |
| Restricted cash, net of current portion | 2,139 | 2,139 |
| Other assets | 293 | 303 |
| Total assets | $435,792 | $398,690 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $2,430 | $1,182 |
Item 1. Financial Statements.
FAQ
- What is Tango Therapeutics's deferred tax assets and other non-current assets?
- Tango Therapeutics (TNGX) reported deferred tax assets and other non-current assets of $293K in Q1 2026.
- How has Tango Therapeutics's deferred tax assets and other non-current assets changed year-over-year?
- Tango Therapeutics's deferred tax assets and other non-current assets increased by 29200.0% year-over-year, from $1K to $293K.
- What is the long-term trend for Tango Therapeutics's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Tango Therapeutics's deferred tax assets and other non-current assets has grown at a 51.5% compound annual growth rate (CAGR), from $38K to $303K.
Ask your AI about Tango Therapeutics's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude